Brickell Biotech Inc
Change company Symbol lookup
Select an option...
BBI Brickell Biotech Inc
VTOL Bristow Group Inc
VTRS Viatris Inc
MSFT Microsoft Corp
NTB Bank of N T Butterfield & Son Ltd
CHN China Fund, Inc.
IGR CBRE Global Real Estate Income Fund
SURRY Sun Art Retail Group Ltd
VPV Invesco Pennsylvania Value Municipal Income Trust
HLBZ Helbiz Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company engaged in developing prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.

Premarket

Last Trade
Delayed
$3.50
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$3.50
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
3,011

10-day average volume:
472,875
3,011

SHAREHOLDER ALERT: AMZN OSCR AXSM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

6:40 pm ET June 29, 2022 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / June 29, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Amazon.com, Inc. (NASDAQ:AMZN)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/amazon-com-inc-loss-submission-form?prid=29382&wire=1

Lead Plaintiff Deadline: July 5, 2022

Class Period: February 1, 2019 - April 5, 2022

Allegations against AMZN include that: (i) Amazon engaged in anticompetitive conduct in its private-label business practices, including giving Amazon products preference over those of its competitors and using third-party sellers' non-public data to compete with them; (ii) the foregoing exposed Amazon to a heightened risk of regulatory scrutiny and/or enforcement actions; (iii) Amazon's revenues derived from its private-label business were in part the product of impermissible conduct and thus unsustainable; and (iv) as a result, the defendants' public statements throughout the class period were materially false and/or misleading.

Oscar Health, Inc. (NYSE:OSCR)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/oscar-health-inc-loss-submission-form?prid=29382&wire=1

Lead Plaintiff Deadline: July 11, 2022

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Oscar Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's March 2021 initial public offering.

Allegations against OSCR include that: (1) Oscar was experiencing growing COVID-19 testing and treatment costs; (2) Oscar was experiencing growing net COVID costs; (3) Oscar would be negatively impacted by an unfavorable prior year Risk Adjustment Data Validation result relating to 2019 and 2020; (4) Oscar was on track to be negatively impacted by significant SEP membership growth; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Axsome Therapeutics, Inc. (NASDAQ:AXSM)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/axsome-therapeutics-inc-loss-submission-form?prid=29382&wire=1

Lead Plaintiff Deadline: July 12, 2022

Class Period: December 30, 2019 - April 22, 2022

Allegations against AXSM include that: (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07, the Company's medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application ("NDA") on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration ("FDA") reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

The Law Offices of Vincent Wong, Wednesday, June 29, 2022, Press release picture

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.

39 East Broadway

Suite 304

New York, NY 10002

Tel. 212.425.1140

Fax. 866.699.3880

E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong





View source version on accesswire.com:

https://www.accesswire.com/707121/SHAREHOLDER-ALERT-AMZN-OSCR-AXSM-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines



comtex tracking

COMTEX_409450549/2457/2022-06-29T18:40:47

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.